Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Trial ID or NCT#
The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.
A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)
- - Ongoing participation in a Phase 2 [LX1606.1-202-CS (NCT00853047), LX1606.1-203-CS (NCT01104415)] or Phase 3 [LX1606.1-301-CS (NCT01677910), LX1606.1-303-CS (NCT02063659)] study - Patients of childbearing potential must agree to use an adequate method of contraception (defined as having a failure rate of <1% per year) during the study and for 12 weeks after the Follow-up visit. - Ability and willingness to provide written informed consent
- - Major protocol violations or tolerability concerns in a Phase 2 (eg, LX1606.1-202-CS, LX1606.1-203-CS) or Phase 3 (eg, LX1606.1-301-CS, LX1606.1-303-CS) study - Positive pregnancy test - Presence of any clinically significant findings at entry for medical history, laboratory values, or physical examination
Contact us to find out if this trial is right for you.